Illumina introduces pan-cancer CDx

Create PDF

July 2022—Illumina announced that a companion diagnostic indication has been added to its CE-marked in vitro diagnostic TruSight Oncology Comprehensive (EU) test. The CDx pan-cancer indication will allow identification of cancer patients with solid tumors who are positive for neurotrophic tyrosine receptor kinase gene fusions including NTRK1, NTRK2, or NTRK3 and who may benefit from targeted therapy with Bayer’s Vitrakvi (larotrectinib), a genomically matched treatment.

Illumina says it has a pipeline of CDx claims in development, through partnerships with pharmaceutical companies, that will be added to TSO Comprehensive (EU) following regulatory approvals.